Skip to main content
QMSQMS
QMS
  • Welcome to your QMS
  • Quality Manual
  • Procedures
  • Records
  • Legit.Health Plus Version 1.1.0.0
  • Legit.Health Plus Version 1.1.0.1
  • Legit.Health version 2.1 (Legacy MDD)
  • Legit.Health US Version 1.1.0.0
  • Legit.Health Utilities
  • Licenses and accreditations
  • Applicable Standards and Regulations
  • BSI Non-Conformities
    • Technical Review
    • Clinical Review
      • Round 1
        • Item 0: Background & Action Plan
        • Item 1: CER Update Frequency
        • Item 2: Device Description & Claims
        • Item 3: Clinical Data
        • Item 4: Usability
        • Item 5: PMS Plan
        • Item 6: PMCF Plan
        • Item 7: Risk
        • completed-tasks
          • task-3b10-legacy-pms-document-hierarchy-refactor
          • task-3b11-sme-coverage-subspecialty-documentation
          • task-3b12-phase-1-exploratory-per-bucket-c-feature
          • task-3b13-man-2025-cep-cip-completeness
          • task-3b14-ifu-integration-requirements-verification
          • task-3b4-mrmc-dark-phototypes
          • task-3b6-surrogate-endpoint-literature-review
            • Appraisal log — CRIT1–7 rolling table
            • Do we need this task?
            • Integration map — propagation of the surrogate-endpoint validity review
            • references
              • diagnostic-accuracy
              • referral-optimisation
              • severity-assessment
                • EMA 2004 — Guideline on clinical investigation of medicinal products for psoriasis (CHMP/EWP/2454/02)
                • Fink 2018 — Inter- and intra-observer variability of image-based PASI
                • Huang 2023 — AI-based PASI severity assessment: real-world study (SkinTeller)
                • King 2022 — Baricitinib BRAVE-AA1 / BRAVE-AA2 (SALT as FDA / EMA primary endpoint)
                • Mattei 2014 — PASI ↔ DLQI correlation in biologic RCTs (r² = 0.80)
                • Mrowietz 2011 — European treat-to-target consensus for moderate-to-severe psoriasis
                • Olsen 2004 — Alopecia areata investigational assessment guidelines (SALT definition, NAAF)
                • Schaap 2022 — CNN-based automated PASI scoring
                • Schmitt 2014 — HOME IV: EASI as core instrument for clinical signs of atopic eczema
                • Simpson 2016 — Dupilumab SOLO 1 and SOLO 2 (EASI / IGA as regulatory primary endpoints)
            • Research prompts — external deep-research tools
            • Surrogate-Endpoint Validity in Dermatology AI — Structured Literature Review
          • task-3b7-icd-per-epidemiological-group-vv
          • task-3b8-safety-confirmation-column-definition
          • task-3b9-legacy-pms-conclusions-into-plus-pms-plan
        • Coverage matrix
        • resources
        • Task 3b-5: Autoimmune and Genodermatoses Triangulated-Evidence Package
      • Evidence rank & phases
      • Pre-submission review of R-TF-015-001 CEP and R-TF-015-003 CER
  • Pricing
  • Public tenders
  • Trainings
  • BSI Non-Conformities
  • Clinical Review
  • Round 1
  • completed-tasks
  • task-3b6-surrogate-endpoint-literature-review
  • references
  • severity-assessment
  • King 2022 — Baricitinib BRAVE-AA1 / BRAVE-AA2 (SALT as FDA / EMA primary endpoint)

King 2022 — Baricitinib BRAVE-AA1 / BRAVE-AA2 (SALT as FDA / EMA primary endpoint)

Citation​

King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022 May 5;386(18):1687–1699. DOI: 10.1056/NEJMoa2110343.

Study design and population​

Two phase-3 RCTs (BRAVE-AA1 and BRAVE-AA2). n = 1,200 adults with severe alopecia areata (baseline SALT ≥ 50; ≥ 50 % scalp hair loss). Multicentre international.

Reported metrics​

  • Week-36 SALT ≤ 20 (primary): BRAVE-AA1 — 38.8 % (4 mg), 22.8 % (2 mg), 6.2 % (placebo); 4 mg vs. placebo difference 32.6 pp (95 % CI 25.6–39.5)
  • BRAVE-AA2 — 35.9 % (4 mg), 19.4 % (2 mg), 3.3 % (placebo); 4 mg difference 32.6 pp (95 % CI 25.6–39.6)
  • Concordant eyebrow and eyelash regrowth (ClinRO) and QoL gains

Surrogate-to-outcome linkage​

Pivotal-trial evidence that SALT (Severity of Alopecia Tool) responds to effective therapy, with SALT ≤ 20 accompanied by patient-relevant outcomes (hair regrowth, self-reported appearance, QoL). Enabled the first FDA and EMA systemic approval for severe alopecia areata. Closes the severity-score → patient-outcome loop for the AA strand of the argument.

CRIT1–7 appraisal​

CriterionScoreJustification
CRIT1 Relevance3Direct — SALT is the AA regulatory surrogate endpoint.
CRIT2 Methodology3Two identical phase-3 placebo-controlled RCTs; regulator-aligned design.
CRIT3 Reporting3Response rates with 95 % CIs; concordant PRO and ClinRO data.
CRIT4 Applicability3Severe AA adults — exact population for SALT surrogate claim.
CRIT5 Evidence weight2Pivotal phase-3 RCTs.
CRIT6 Risk of bias2Industry-funded (Eli Lilly); 36-week primary endpoint.
CRIT7 Contribution3Core anchor — FDA / EMA approval precedent for SALT.

Aggregate: very strong.

Limitations and notes​

Industry-funded; short primary endpoint horizon. Complementary ritlecitinib ALLEGRO and deuruxolitinib data available for triangulation if needed.

Strength as anchor​

Very strong for the AA strand. Pairs with Olsen 2004 (SALT definition) and the subsequent ritlecitinib / deuruxolitinib approvals to anchor SALT as the regulator-accepted AA severity surrogate.

Previous
Huang 2023 — AI-based PASI severity assessment: real-world study (SkinTeller)
Next
Mattei 2014 — PASI ↔ DLQI correlation in biologic RCTs (r² = 0.80)
  • Citation
  • Study design and population
  • Reported metrics
  • Surrogate-to-outcome linkage
  • CRIT1–7 appraisal
  • Limitations and notes
  • Strength as anchor
All the information contained in this QMS is confidential. The recipient agrees not to transmit or reproduce the information, neither by himself nor by third parties, through whichever means, without obtaining the prior written permission of Legit.Health (AI Labs Group S.L.)